<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055831</url>
  </required_header>
  <id_info>
    <org_study_id>19-LDRTC-01</org_study_id>
    <nct_id>NCT04055831</nct_id>
  </id_info>
  <brief_title>Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease</brief_title>
  <official_title>Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lysosomal and Rare Disorders Research and Treatment Center, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lysosomal and Rare Disorders Research and Treatment Center, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone-related problems represent the principal unmet medical need in Gaucher disease (GD). 75%
      of GD type 1 patients develop skeletal complications, including bone remodeling defects,
      osteopenia, osteoporosis, marrow infiltration, avascular necrosis, and osteolysis. However,
      the underlying cellular/molecular basis of bone involvement and related complications in GD
      are not fully known. Neither are there any bone-specific markers associated with individual
      bone pathology. Early diagnosis of bone disease is the key issue for planning individual
      therapy to prevent and reverse bone disease in GD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical observational study is designed to identify specific biomarkers for bone
      involvement in patients with GD1 with decreased bone density and/or bone structural
      abnormalities

      Aims:

        1. Identify novel immune cell surface and biochemical markers in peripheral blood
           correlating with bone involvement in GD.

        2. Assess the correlation between cytokine levels in peripheral blood and the severity of
           bone involvement in GD.

        3. Assess the relationship between glycosphingolipids accumulation and macrophage
           activation with specific bone markers and GD severity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">May 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure biomarkers level in molar/l/h</measure>
    <time_frame>18 months</time_frame>
    <description>Bone homeostasis is dependent on the balance of deposition by osteoblasts
DMP-1, OSCAR, Calcitonin, Lyso-GB1, chitotriosidase, CCL18, osteocalcin, BALP, cathepsin K , TRAP 5, RANKL, OPG, DDK-1, sclerostin, MCP1, IL-2, IL-6, IL-10, SRTH2 and TNF-Î±</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure biomarkers level: molar/mg/h</measure>
    <time_frame>18 months</time_frame>
    <description>DMP-1, RANK, OSCAR, cathepsin K, OPG</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gaucher Disease Type 1</condition>
  <arm_group>
    <arm_group_label>GD1 subjects with no bone complications</arm_group_label>
    <description>1. GD1 subjects with no bone complications (n=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GD1 patients with mild bone complication</arm_group_label>
    <description>2. GD1 subjects with mild bone complications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GD1 with severe bone complications</arm_group_label>
    <description>3. GD1 subjects with severe bone complications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No bone disease</arm_group_label>
    <description>Controls with no known bone disease (n=10)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, PBMC, and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Clinically confirmed GD1 patients will be stratified based on their disease severity and
        bone density findings.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be enrolled in this study the subject must meet the following criteria

               1. Subject is greater than 16 years old but not older than 90 years

               2. Signed Informed Consent/Assent

               3. Subject is able and willing to sign informed consent or assent

               4. If the subject has GD1, the must have a confirmed diagnosis of Gaucher disease by

                    -  GCase enzyme activity

                    -  DNA analysis demonstrating pathogenic variants in the GBA gene

        Exclusion Criteria:

          -  a) Have evidence of hepatitis B, hepatitis C infection or any other chronic infectious
             disease b) Be pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ozlem Goker-Alpan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lysosomal and Rare Disorders Research and Treatment Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline Fikry</last_name>
    <phone>571-732-4575</phone>
    <email>jfikry@ldrtc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margarita Ivanova, PhD</last_name>
    <phone>5715296724</phone>
    <email>mivanova@ldrtc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LDRTC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozlem Goker-Alpan, MD</last_name>
      <phone>703-261-6220</phone>
      <email>ogokar-alpan@ldrtc.org</email>
    </contact>
    <contact_backup>
      <last_name>Margarita M Ivanova, PhD</last_name>
      <phone>7032616220</phone>
      <phone_ext>5022957709</phone_ext>
      <email>mivanova@ldrtc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ozlem Goker-Alpan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Ivanova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gaucher disease</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

